Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.

Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know

CAMBRIDGE, Mass. and CORALVILLE, Iowa, July 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Integrated DNA Technologies, Inc. (IDT), a leading comprehensive genomics research solutions provider, today announced the publication of research data demonstrating the advantages of Alt-R™ A.s. Cas12a (Cpf1) Ultra, an engineered AsCas12a nuclease variant, as a tool to eventually enable the development of gene-edited cell medicines. The findings were published in the journal Nature Communications .

Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines

Dr. Eaton joined the Company in 2018 and brings more than 30 years of experience to the role

Editas Medicine Names Bruce E. Eaton, Ph.D.

Luminar Technologies

Many science fiction concepts are turning into disruptive realities and creating enormous investment opportunities. The post The Top 2 Stocks to Buy to Play the Emerging Exoskeleton Megatrend appeared first on InvestorPlace.

The Top 2 Stocks to Buy to Play the Emerging Exoskeleton Megatrend

IGM Biosciences Inc

Ionis Pharma

Xencor

Zymeworks Inc

These biotech stocks could have great long-term potential.

5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021

ARK Innovation ETF

Goldman Sachs Innovate Equity ETF

ROBO Global Healthcare Technology and Innovation ETF

First Trust Innovation Leaders ETF

Microsoft

When it comes to innovation and making your world a better place, these are the best ETFs to buy to meet your objectives while making money.  The post 7 Best ETFs to Buy That Will Make Your World a Better Place appeared first on InvestorPlace.

7 Best ETFs to Buy That Will Make Your World a Better Place

EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term. The post Editas Stock Isn't Worth Buying This Early Into Treatment Development appeared first on InvestorPlace.

Editas Stock Isn't Worth Buying This Early Into Treatment Development

Beam Therapeutics

CRISPR Therapeutics

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week

Intellia Therapeutics

It's a good time to be a gene-editing company.

After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding

Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.

The Top 3 Gene Editing Stocks to Own for the Next Decade

Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.

Do Options Traders Know Something About Editas Medicine (EDIT) Stock We Don't?

Alnylam Pharmaceuticals

BioNTech SE

Moderna

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Here's What Drove Gene Editing Stocks Higher This Week

Cellectis SA

Calyxt

Sangamo Therapeutics

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared first on InvestorPlace.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

The rally for gene-editing stocks has entered its third day.

Editas Medicine: An Undervalued, Gene-Editing Stock

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. The post Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar appeared first on InvestorPlace.

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar

Novavax

Biotech stocks can be risky. If a clinical trial fails, you could very well lose your money.

The 3 Biotech Firms Riding High on CRISPR News

bluebird bio

CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agriculture, chemical, pharmaceutical, and livestock industries.

CRISPR: 4 Emerging Players

The stock price of Editas Medicine Inc (NASDAQ: EDIT) increased by over 5% during intraday trading. This is why it happened.

EDIT Stock Price Increases Over 5%: Why It Happened

The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.

Why Editas Medicine Stock Is Jumping 13.9% This Week

Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.

Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study

IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D. In connection with the appointments, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to each of Drs. Shearman and Li as inducements material to their entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  Drs. Shearman's and Li's stock options provide for the purchase of up to 52,718 shares and 44,202 shares, respectively, of Editas Medicine common stock at a price of $38.53 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vest over four years, with 25 percent of the shares vesting on the first anniversary of each individual's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to their continued service relationship with Editas Medicine through the applicable vesting dates. Drs. Shearman's and Li's restricted stock unit awards are for 32,701 shares and 14,144 shares, respectively, of Editas Medicine common stock and vest as to 25 percent of the shares on each one-year anniversary of their employment start date until the fourth anniversary of their employment start date, subject to their continued service to Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer

Mark S. Shearman, Ph.D., joins as Chief Scientific Officer

Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

Invitae

Here are some of our experts' favorite gene editing plays for the long run.

News for Editas Medicine Stock (EDIT)